Among doctors, Google outpaces professional search engines

Share this article:

Even among physicians, Dr. Google reigns supreme. Double the number of MDs used the consumer search engine (87%) for professional research online as the next most-used search options (WebMD and PubMed, each at 43%), data from a recent survey show.

Google was one of six consumer search options (out of 12 mentioned in the survey) drawing significant usage; each was tapped by an average of 23% of doctors. That's the same percentage that used each of the six medical sites on average, researchers from Kantar Media found.


The data come from Kantar's Sources & Interactions 2011 survey, a study of healthcare professionals' touch points with pharma and professional media. In the physicians study, 2,983 US-based physicians were surveyed by mail and online during the first half of 2011 to document what professional sources of information they rely on.


Kantar also found wide variations in reported usage based on specialty, age and other demographic factors. Google and Yahoo! were consistent performers across most groups, Kantar said, generally within a two- or three-point range of average. For other sites, usage varied. Only 29% of family medicine doctors rely on PubMed, but 77% of infectious disease specialists do.

Older users tended to gravitate toward PubMed and Google Scholar, while the younger set more often tapped general search engines Yahoo! and Bing, as well as WebMD and MDLinx.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...